Foundayo Tablets — a weight loss tablet you take once a day

Foundayo is a prescription-only weight loss tablet containing orforglipron. It acts on the GLP-1 appetite pathway, the same pathway used by well-known weekly injections, reducing appetite and slowing stomach emptying so that smaller meals feel satisfying. It is taken once a day and is licensed for weight management alongside diet and activity changes.

Orforglipron is the active ingredient in Foundayo and the first non-peptide GLP-1 receptor agonist available as a tablet. Because it is a small molecule rather than a peptide, it is not broken down by stomach acid, which is why it can be swallowed at any time of day without fasting rules. It is made by Eli Lilly.

One tablet is taken once a day, at any time of day, with or without food. It is swallowed whole with a drink of water and must not be cut, crushed or chewed. There is no fasted window, no restriction on how much water is used and no waiting period before eating or taking other medicines.

No. Unlike oral semaglutide, orforglipron does not require an empty stomach, a limited sip of water or a 30-minute wait. Absorption is not meaningfully affected by food, so the tablet can be taken with a meal or between meals, whichever fits the day better.

There are six strengths: 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg and 17.2mg. Treatment starts at 0.8mg and increases roughly every 30 days if it is being tolerated. There is no requirement to reach the top strength, and a prescriber may hold or reduce a dose if side effects are troublesome or results are already good.

The most common are nausea, diarrhoea, constipation, being sick, indigestion and reduced appetite, affecting more than one person in ten. They are usually mild, worst in the first week after a dose increase and settle within a few days. Uncommon but serious effects include pancreatitis and gallbladder inflammation, which need urgent medical assessment.

Orforglipron is a licensed prescription-only medicine and is considered safe for most eligible adults when prescribed and monitored by a registered clinician. Side effects are common but usually mild, short-lived and confined to the stomach and bowel. It is not suitable for everyone, including people who are pregnant or breastfeeding, or who have a history of medullary thyroid cancer, MEN 2 or pancreatitis.

It is not prescribed in pregnancy, breastfeeding or while trying to conceive, nor to anyone with a history of medullary thyroid cancer or multiple endocrine neoplasia type 2, previous pancreatitis, type 1 diabetes or diabetic ketoacidosis. It is also unsuitable alongside another GLP-1 medicine, and caution applies in severe gastrointestinal disease such as gastroparesis.

The missed tablet can be taken as soon as it is remembered, unless the next dose is due within about eight hours, in which case it should be skipped. Two tablets must never be taken on the same day. Because the medicine has a half-life of roughly 29 to 49 hours, a single missed day has little effect on treatment.

No. The tablet is swallowed whole. Cutting, crushing or chewing it changes how quickly the dose is released and makes the effect less predictable. Anyone who cannot swallow tablets should discuss alternatives with their prescriber.

No. Tablets are stored in their original blister at room temperature below 30 degrees, away from damp. That makes travel straightforward: hand luggage, no cool bag, no cold-chain delivery and no sharps declaration.

There is no absolute contraindication, but alcohol is best limited. It irritates a stomach that is already emptying more slowly, which makes nausea and reflux more likely, and it can lower blood sugar in people also taking insulin or a sulfonylurea. It is also calorie dense, which works against the aim of treatment.

Yes. Orforglipron is a prescription-only medicine and cannot lawfully be sold over the counter. A UK-registered prescriber must review the medical history and confirm treatment is appropriate, and the medicine must be dispensed by a registered pharmacy. Any product offered without a prescription should be treated as unsafe or counterfeit.

Possibly. Slower stomach emptying and any vomiting can reduce absorption of the combined oral contraceptive pill, particularly in the weeks after starting and after each dose increase. Additional barrier contraception or a non-oral method is advised during those periods. Orforglipron must not be used in pregnancy.

Its half-life is around 29 to 49 hours, so the medicine clears from the body over roughly seven to ten days after the last tablet. Appetite usually returns gradually across that period rather than suddenly, which is why stopping is best planned with a prescriber.

Often yes, but the switch is not dose-for-dose and must be planned by a prescriber. The gap after the last injection, the starting strength and the speed of any increase are all set individually. Because average weight loss is lower with the tablet, the reasons for switching are usually practical rather than clinical.

Private prices vary by strength and provider, generally from around £100 to £250 for a month. It is worth checking whether the price includes the prescriber review, delivery and ongoing support, as some services charge for these separately. At ClariDay, prices start at £120 a month with no separate consultation fee, and every strength is listed on this page.

It has been studied in adults with type 2 diabetes, where it improved blood sugar control as well as reducing weight. Whether it is appropriate depends on current medicines, as insulin and sulfonylurea doses usually need reducing to avoid low blood sugar. This is a decision for a prescriber who can see the full medical picture.